Dawes Karen A

Dawes Karen A is listed in filings as Director at Repligen Corp. This profile follows SEC Form 4 activity through May 18, 2026, including sale activity. Recent filings connect the profile to Repligen Corp (RGEN) and Barinthus Biotherapeutics plc (BRNS). The current snapshot covers public activity from Jun 14, 2024 to May 18, 2026. Reported amounts are shown as $231.5K to $20.2K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.